A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

NCT02956122 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped The decision to discontinue the study was based on business reasons.

Conditions

Graft Versus Host Disease

Interventions

BIOLOGICAL: GLASSIA
DRUG: methylprednisolone or equivalent steroid
BIOLOGICAL: Albumin

Sponsor

Baxalta now part of Shire

Collaborators

[object Object]